|
|
Volumn 16, Issue 5, 2017, Pages 309-310
|
|
Trends in the market for antihypertensive drugs
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
AMBRISENTAN;
AMLODIPINE;
ANTIHYPERTENSIVE AGENT;
AZILSARTAN;
BOSENTAN;
CANDESARTAN HEXETIL;
CHLORTALIDONE;
CS 3150;
ESUBERAPROST;
FIMASARTAN;
HCP 1305;
HCP 1401;
HYDROCHLOROTHIAZIDE;
LOSARTAN;
MACITENTAN;
NIFEDIPINE;
NITRIC OXIDE;
RIOCIGUAT;
SELEXIPAG;
TADALAFIL;
TELMISARTAN;
UNCLASSIFIED DRUG;
CALCIUM CHANNEL BLOCKING AGENT;
BLOOD PRESSURE REGULATION;
CARDIOVASCULAR DISEASE;
CARDIOVASCULAR MORTALITY;
CARDIOVASCULAR RISK;
DISEASE ASSOCIATION;
DRUG COST;
DRUG EFFICACY;
DRUG MARKETING;
ESSENTIAL HYPERTENSION;
HUMAN;
HYPERTENSION;
MONOTHERAPY;
MORBIDITY;
PULMONARY HYPERTENSION;
SHORT SURVEY;
TREATMENT RESPONSE;
TREND STUDY;
VASODILATATION;
ANIMAL;
DRUG INDUSTRY;
ECONOMICS;
HEALTH CARE COST;
TRENDS;
ANIMALS;
ANTIHYPERTENSIVE AGENTS;
CALCIUM CHANNEL BLOCKERS;
DRUG INDUSTRY;
HEALTH CARE SECTOR;
HUMANS;
HYPERTENSION;
|
|
EID: 85014701061
PISSN: 14741776
EISSN: 14741784
Source Type: Journal
DOI: 10.1038/nrd.2016.262 Document Type: Short Survey |
|
Times cited : (28)
|
|
References (0)
|
